Division of Nephrology, Department of Medicine, Saint Louis University Center for Abdominal Transplantation, St. Louis, MO.
Division of Nephrology, Department of Medicine, University of Nebraska Medical Center and Medical Service, Nebraska-Western Iowa Veterans Affairs Medical Center, Omaha, NE.
Am J Kidney Dis. 2021 May;77(5):777-785. doi: 10.1053/j.ajkd.2020.12.003. Epub 2021 Jan 1.
The coronavirus disease 2019 (COVID-19) pandemic required transplant nephrologists, surgeons, and care teams to make decisions about the full spectrum of transplant program operations and clinical practices in the absence of experience or data. Initially, across the country, there was a reduction in kidney transplant procedures and a striking pause in the conduct of living donation and living-donor transplant surgeries. Aspects of candidate evaluation and follow-up rapidly converted to telehealth. Months into the pandemic, much has been learned from experiences worldwide, yet many questions remain. In this Perspective, we reflect on some of the practice decisions made by the transplant community in the initial response to the pandemic and consider lessons learned, including those related to the risks, benefits, and logistical considerations of proceeding with versus delaying deceased-donor transplantation, living donation, and living-donor transplantation during the pandemic. We review the evolution of therapeutic strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their use in transplant recipients, current consensus related to immunosuppression management in infected transplant recipients, and emerging information on vaccination against SARS-CoV-2. We share our thoughts on research priorities, discuss the areas in which we are still practicing with uncertainty, and look ahead to the next phase of the pandemic response.
2019 年冠状病毒病(COVID-19)大流行使得移植肾脏病学家、外科医生和护理团队在缺乏经验或数据的情况下,必须对移植项目的各个方面和临床实践做出决策。最初,全美范围内肾脏移植手术减少,活体供者和活体供者移植手术数量显著减少。候选者评估和随访的各个方面迅速转为远程医疗。大流行发生数月后,全球范围内已经吸取了许多经验教训,但仍有许多问题悬而未决。在本观点文章中,我们回顾了移植界在应对大流行初始阶段所做出的一些实践决策,并考虑了经验教训,包括在大流行期间进行遗体器官移植、活体捐赠和活体供者移植的风险、获益和后勤方面的考虑,以及与感染 SARS-CoV-2 的移植受者相关的治疗策略的演变及其在移植受者中的应用、感染移植受者免疫抑制管理方面的当前共识,以及针对 SARS-CoV-2 的疫苗接种的新信息。我们分享了对研究重点的看法,讨论了我们在哪些方面仍存在不确定性,并展望了大流行应对的下一阶段。